Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Simpson EL, et al. Among authors: galimberti r. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. Br J Dermatol. 2020. PMID: 31995838
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS Investigators. Paller AS, et al. JAMA Dermatol. 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655. JAMA Dermatol. 2022. PMID: 35416908 Free PMC article. Clinical Trial.
[Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].
Máspero J, Angles MV, Ardusso L, Brancciforte M, Castro C, Cruz Iturrieta C, Chouela E, De Gennaro MS, Fernández Bussy R, Galimberti ML, Galimberti RL, Gattolin G, Luna PC, Magariños G, Marini MG, Maskin M, Plafnik R, Raimondo N, Russo JP, Sevinsky L, Stringa MF. Máspero J, et al. Among authors: galimberti rl. Rev Fac Cien Med Univ Nac Cordoba. 2020 Jun 9;77(2):94-99. doi: 10.31053/1853.0605.v77.n2.27845. Rev Fac Cien Med Univ Nac Cordoba. 2020. PMID: 32558511 Spanish.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
Valenzuela F, de la Cruz Fernandez C, Galimberti RL, Gürbüz S, McKean-Matthews M, Goncalves L, Romiti R. Valenzuela F, et al. Among authors: galimberti rl. Actas Dermosifiliogr. 2017 Jul-Aug;108(6):550-563. doi: 10.1016/j.ad.2017.02.005. Epub 2017 Mar 23. Actas Dermosifiliogr. 2017. PMID: 28342534 Free article. Clinical Trial. English, Spanish.
Cutaneous aspergillosis: a report of six cases.
Galimberti R, Kowalczuk A, Hidalgo Parra I, Gonzalez Ramos M, Flores V. Galimberti R, et al. Br J Dermatol. 1998 Sep;139(3):522-6. doi: 10.1046/j.1365-2133.1998.02424.x. Br J Dermatol. 1998. PMID: 9767305
Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial.
Thaçi D, Galimberti R, Amaya-Guerra M, Rosenbach T, Robertson D, Pedersen R, Yang S, Kuligowski M, Boggs R. Thaçi D, et al. Among authors: galimberti r. J Eur Acad Dermatol Venereol. 2014 Jul;28(7):900-6. doi: 10.1111/jdv.12207. Epub 2013 Jul 15. J Eur Acad Dermatol Venereol. 2014. PMID: 23848989 Clinical Trial.
Cutaneous phaeohyphomycosis.
Caviedes MP, Torre AC, Eliceche ML, Valdivia Monteros DC, Volonteri VI, Galimberti RL. Caviedes MP, et al. Int J Dermatol. 2017 Apr;56(4):415-420. doi: 10.1111/ijd.13590. Int J Dermatol. 2017. PMID: 28295266
79 results